vertex pharmaceuticals journavx

FDA Approves Vertex Pharma's JOURNAVX

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

Business Insider · 1h

Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to

Pharmaceutical Technology · 6h

FDA approves Vertex’s acute pain treatment Journavx

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

AFP7h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has largely ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA Approves Vertex Pharma's JOURNAVX

Trending now